Skip to main content
. 2021 Jun 9;596(7871):268–272. doi: 10.1038/s41586-021-03681-2

Fig. 1. Neutralizing and binding antibody responses to SARS-CoV-2 variants.

Fig. 1

a, SARS-CoV-2 psVNA responses against WA1/2020, D614G, B.1.1.7, CAL.20C, P.1 and B.1.351 (a), RBD-specific binding antibodies by ELISA against WA1/2020, B.1.1.7, P.1 and B.1.351 (b) and RBD-specific and spike (S)-specific binding antibodies by ECLA against WA1/2020, B.1.1.7, P.1 and B.1.351 (Meso Scale Discovery panel 7) (c) on days 57 and 71. Red bars reflect median responses. Dotted lines reflect the lower limits of quantification. Filled squares denote placebo–placebo; filled circles denote high dose–placebo; open circles denote high dose–high dose; filled triangles denote low dose–placebo; and open triangles denote low dose–low dose. n = 25 independent samples (5 placebo recipients, 20 Ad26.COV2.S vaccine recipients).